Is there any consensus or guidance on how to manage germ cell tumor patients in the COVID-19 era?

Germ Cell Tumor Management in face of SARS-CoV-2: Safe, Rational Modifications to Standard GCT Practice to Protect Public Health, GCT Outcomes, GCT Patients, and Health Systems.

This bulletin has been produced by a concerned group of international experts in germ cell tumors, has not undergone extensive peer-review and is not based on clinical data from germ cell tumor patients in the COVID-19. Keeping our obligations to public health, our patients and our health care systems in mind, these are ...